Amchi Gendynamy Science S-1/A 19 Sep 16 2016 Q2 IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Sep. 16, 2016
Document Information [Line Items]
Entity Registrant Name	Amchi Gendynamy Science Corp
Entity Central Index Key	1,610,764
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		27,207,994
Document Type	S-1/A
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Amendment Flag	true
Amendment Description	This registration statement and the prospectus therein cover the registration of or 27,207,994 shares of common stock offered by the holders thereof. The information contained in this prospectus is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and these securities may not be sold until that registration statement becomes effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 59,837	$ 0
Prepaid expense	7,400
Total Current Assets	67,237
Other assets:
Patent and Trademark	10,400
Total Assets	77,637
Current liabilities
Accounts payable	15,000
Payable to related party	102,172
Short term advances	60,445
Total Current Liabilities	177,617
Total Liabilities	177,617
Commitments and contingencies (Note 5)
Stockholders' Equity (Deficit)
Preferred Stock, $0.0001 par value, 20,000,000 shares were authorized; none issued and outstanding at December 31, 2015 and 2014.
Common stock, $0.0001 par value, 500,000,000 shares authorized; 20,500,000 shares 20,000,000 shares issued and outstanding at December 31, 2015 and 2014, respectively	2,050	2,000
Discount on common stock	(2,050)	(2,000)
Additional paid in capital	1,751	707
Deficit accumulated during development stage	(101,731)	(707)
Total Stockholders' Equity (Deficit)	(99,980)
Total Liabilities and Stockholders' Equity	$ 77,637

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2016	Dec. 31, 2015	Oct. 20, 2015	Oct. 19, 2015	Oct. 02, 2015	Dec. 31, 2014
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001			$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000			20,000,000	20,000,000
Preferred stock, shares issued (in shares)	0	0				0
Preferred stock, shares outstanding (in shares)	0	0				0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001				$ 0.0001
Common stock, shares authorized (in shares)	500,000,000	500,000,000	500,000,000	100,000,000		500,000,000
Common stock, shares issued (in shares)	247,207,994	20,500,000				20,000,000
Common stock, shares outstanding (in shares)	247,207,994	20,500,000				20,000,000

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		6 Months Ended		7 Months Ended	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2015
Revenue
Cost of revenue
Gross profit
Operating expenses
General and administrative	70,660		116,876		707	101,024
Total operating expenses	70,660		116,876		707	101,024
Operating loss from operations	(70,705)		(116,876)		(707)	(101,024)
Other income (expenses)	21		46
Loss from operations before income taxes	(70,639)		(116,830)		(707)	(101,024)
Provision for income tax
Net loss	$ (70,639)		$ (116,830)	$ 0	$ (707)	$ (101,024)
Basic and diluted net loss per share (in dollars per share)	$ 0		$ 0		$ 0	$ (0.01)
Weighted average number of shares outstanding (in shares)	247,207,994	20,000,000	216,875,599	20,000,000	20,000,000	20,052,055

Statement of Changes in Stockho

Statement of Changes in Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Discount on Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at May. 19, 2014
Balance at May. 19, 2014
Issuance of shares to founders (in shares)	20,000,000
Issuance of shares to founders	$ 2,000	(2,000)
Contribution of capital			707		707
Net loss				(707)	(707)
Balance (in shares) at Dec. 31, 2014	20,000,000
Balance at Dec. 31, 2014	$ 2,000	(2,000)	707	(707)
Issuance of shares to founders (in shares)	20,000,000
Issuance of shares to founders	$ 2,000	(2,000)
Contribution of capital			1,044		1,044
Net loss				(101,024)	(101,024)
Balance (in shares) at Dec. 31, 2015	20,500,000
Balance at Dec. 31, 2015	$ 2,050	(2,050)	$ 1,751	$ (101,731)	(99,980)
Redemption of shares (in shares)	(19,500,000)
Redemption of shares	$ (1,950)	$ 1,950
Net loss					(116,830)
Balance at Jun. 30, 2016					$ 450,845

Statements of Cash Flows

Statements of Cash Flows - USD ($)	7 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2015
Cash Flows from Operating Activities
Net loss	$ (707)	$ (101,024)
Adjustment to reconcile net loss to net cash provided by operating activities:
Expenses paid by stockholder and contributed as capital	707	1,044
Changes in operating assets and liabilities
Prepaid expense	0	(7,400)
Accounts payable	0	85,000
Payable to related party	0	32,172
Net cash provided by operating activities	0	9,792
Cash Flows from Investing Activities:
Cash paid for patents and trademarks	0	(10,400)
Net cash used in investing activities	0	(10,400)
Cash Flows from Financing Activities:
Cash proceeds from short term advances	0	60,445
Net cash provided by financing activities	0	60,445
Net increase in cash and cash equivalents	0	59,837
Cash and cash equivalents, beginning of the period	0	0
Cash and cash equivalents, end of the period	0	59,837
Supplemental disclosures of cash flow information:
Cash paid for income taxes	0	0
Cash paid for interest	0	0
Supplemental disclosures of non-cash investing and financing activities:
Settlement of accounts payable by related party	0	102,173
Discount on common stock	$ 0	$ 50

Balance Sheets (Current Period

Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current Assets
Cash and cash equivalents	$ 324,386	$ 59,837
Prepaid expense		7,400
Other current asset	148,571
Total Current Assets	472,957	67,237
Other assets:
Patent and Trademark	30,400	10,400
Total Assets	503,357	77,637
Current liabilities
Accounts payable	5,000	15,000
Accrued liabilities	5,153
Officer's compensation payable	30,000
Payable to related party	12,359	102,172
Deposits		60,445
Total Current Liabilities	52,512	177,617
Total Liabilities	52,512	177,617
Stockholders' Equity (Deficit)
Preferred Stock, $0.0001 par value, 20,000,000 shares were authorized; none issued and outstanding at December 31, 2015 and 2014.
Common stock, $0.0001 par value, 500,000,000 shares authorized; 20,500,000 shares 20,000,000 shares issued and outstanding at December 31, 2015 and 2014, respectively	24,721	2,050
Discount on common stock	(2,050)	(2,050)
Additional paid in capital	646,735	1,751
Deficit accumulated during development stage	(218,561)	(101,731)
Total Stockholders' Equity (Deficit)	450,845	(99,980)
Total Liabilities and Stockholders' Equity	$ 503,357	$ 77,637

Balance Sheets (Current Period8

Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2016	Dec. 31, 2015	Oct. 20, 2015	Oct. 19, 2015	Oct. 02, 2015	Dec. 31, 2014
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001			$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000			20,000,000	20,000,000
Preferred stock, shares issued (in shares)	0	0				0
Preferred stock, shares outstanding (in shares)	0	0				0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001				$ 0.0001
Common stock, shares authorized (in shares)	500,000,000	500,000,000	500,000,000	100,000,000		500,000,000
Common stock, shares issued (in shares)	247,207,994	20,500,000				20,000,000
Common stock, shares outstanding (in shares)	247,207,994	20,500,000				20,000,000

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended		7 Months Ended	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2015
Revenue
Cost of revenue
Gross Profit
Operating expenses
General and administrative	70,660		116,876		707	101,024
Operating Expenses	70,660		116,876		707	101,024
Operating Loss From Operations	(70,705)		(116,876)		(707)	(101,024)
Other income (expenses)	21		46
Loss From Operations Before Income Tax	(70,639)		(116,830)		(707)	(101,024)
Provision for income tax
Net Income (Loss) Attributable to Parent	$ (70,639)		$ (116,830)	$ 0	$ (707)	$ (101,024)
Basic and diluted net loss per share (in dollars per share)	$ 0		$ 0		$ 0	$ (0.01)
Weighted average number of shares outstanding (in shares)	247,207,994	20,000,000	216,875,599	20,000,000	20,000,000	20,052,055

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash Flows from Operating Activities
Net loss	$ (116,830)	$ 0
Adjustment to reconcile net loss to net cash provided by operating activities:
Expenses paid by stockholder and contributed as capital	0	0
Changes in operating assets and liabilities
Prepaid expense	7,400	0
Other current asset	(148,571)	0
Accounts payable	(10,000)	0
Accrued liabilities	5,153	0
Officer's compensation payable	30,000	0
Net Cash Provided by (Used in) Operating Activities, Continuing Operations	(232,848)	0
Cash Flows from Investing Activities	0	0
Cash Flows from Financing Activities:
Cash proceeds from short term advances	2,500	0
Cash paid to related party against advances	(92,313)	0
Cash proceeds from sale of common stock	587,210	0
Net cash provided by financing activities	497,397	0
Net Increase in Cash and Cash Equivalents	264,549	0
Cash and cash equivalents, beginning of the period	59,837	0
Cash and cash equivalents, end of the period	324,386	0
Supplemental disclosures of cash flow information:
Cash paid for income taxes	0	0
Cash paid for interest	0	0
Supplemental disclosures of non-cash investing and financing activities:
Conversion of deposits received into issuance of common stock	60,445	0
Assignment of patent and trademark in exchange of common stock	$ 20,000	$ 0

Note 1 - Nature of Operations a

Note 1 - Nature of Operations and Going Concern	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 1 – NATURE OF OPERATIONS AND GOING CONCERN As used herein and except as otherwise noted, the term “Company”, “it(s)”, “our”, “us”, “we” and “Amchi” shall mean Amchi Gendynamy Science Corporation, a Delaware corporation. Amchi Gendynamy Science Corporation, formerly known as Pretty Valley Acquisition Corporation, was incorporated on May 20, 2014 under the laws of the state of Delaware. On June 18, 2014, Pretty Valley Acquisition Corporation filed a registration statement with the Securities and Exchange Commission on Form 10 by which it became a public reporting company. In September, 2015, the Company implemented a change of control by redeeming shares of existing shareholders, issuing shares to new shareholders, electing new officers and directors and accepting the resignations of its then existing officers and directors. In connection with the change of control, the shareholders of the Company and its board of directors unanimously approved the change of the Company’s name from Pretty Valley Acquisition Corporation to Amchi Gendynamy Science Corporation. The Company has been formed to provide a method for a foreign or domestic private company to become a reporting company with a class of securities registered under the Securities Exchange Act of 1934. The Company is an early-stage development company using a special designed message machine along with acoustic wave to replace medicine and insulin to help diabetes patients to recovery from high blood sugar and medicine side effects. In China, Amchi is one of a few companies in the field of developing a physical method to treat Diabetes, utilizing electrical frequencies and special acoustic waves, which the founder of the Company has devoted many years in researching this Chinese traditional sound wave treatment. The Company has been working to determine what is the right multiple frequency, and how this frequency works on Diabetes to lower blood sugar. The Company’s research is in its early stages and there is no assurance that its therapy protocol or its energy devices will ever be able to be proved and accepted by the scientific and medical communities. Going Concern The Company’s financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet generated any revenue and has sustained operating losses since inception to date and allow it to continue as a going concern. The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, the ability of the Company to obtain necessary financing to continue operations, and the attainment of profitable operations. The Company incurred a net loss of $116,830 for the six months ended June 30, 2016, used net cash in operating activities of $232,848, has a working capital surplus of $420,445, and has an accumulated deficit of $218,561as of June 30, 2016. These factors, among others raise a substantial doubt regarding the Company’s ability to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations. The accompanying financial statements do not include any adjustments to reflect the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.	NOTE 1 – NATURE OF OPERATIONS AND GOING CONCERN As used herein and except as otherwise noted, the term “Company”, “it(s)”, “our”, “us”, “we” and “Amchi” shall mean Amchi Gendynamy Science Corporation, a Delaware corporation. Amchi Gendynamy Science Corporation (formerly Pretty Valley Acquisition Corporation ("Amchi Gendynamy" or the "Company") was incorporated on May 20, 2014 under the laws of the state of Delaware to engage research and develop Dynamic recovery and therapy system, we will concentrated on develop the theory and application of Dynamic recovery and therapy Device, will continue to commercialize such Device around the world. We own the technology of Dynamic recovery and therapy technology, not bought for the others. Going Concern The Company’s financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet generated any revenue and has sustained operating losses since inception to date and allow it to continue as a going concern. The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, the ability of the Company to obtain necessary financing to continue operations, and the attainment of profitable operations. The Company incurred a net loss of $101,024 for the year ended December 31, 2015, provided net cash in operating activities of $9,792, had a working capital deficit of $110,380, and has an accumulated deficit of $101,731 as of December 31, 2015. These factors, among others raise a substantial doubt regarding the Company’s ability to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations. The accompanying financial statements do not include any adjustments to reflect the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The following summary of significant accounting policies of the Company is presented to assist in the understanding of the Company’s financial statements. The financial statements and notes are the representation of the Company’s management who is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America ("GAAP") in all material respects, and have been consistently applied in preparing the accompanying financial statements. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates of valuation of equity instruments. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and on deposit at the banking institutions. The Company did not have cash equivalents as of June 30, 2016 and December 31, 2015, respectively. Concentration of Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and other current asset. The Company places its cash with high quality banking institutions. The Company has the cash balances in excess of the Federal Deposit Insurance Corporation limit as of June 30, 2016 and not as of December 31, 2015. Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “ Income Taxes” The Company follows the provisions of ASC 740-10, “ Accounting for Uncertain Income Tax Positions Earnings (Loss) Per Common Share The Company computes net earnings (loss) per share in accordance with ASC 260, “ Earnings per Share” Fair value of Financial Instruments and Fair Value Measurements ASC 820, “ Fair Value Measurements and Disclosures”, Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments consist principally of cash, other current asset, accounts payable, payable to a related party and short term deposits. Pursuant to ASC 820 and ASC 825, “ Financial Instruments” Patent Rights and Trademark Patent rights and trademarks which are stated at cost, relate to the cost of applications submitted for obtaining patent and trademark of our Genome Repair Device, a non-invasive treatment device. Cost is based on third party expenditures for patent applications. We will begin amortizing our patent rights and trademark over their estimated remaining useful life when we begin revenue-producing activities. We will determine the useful lives of patent rights and trademark after considering the specific facts and circumstances related to each such asset. Factors we consider when determining useful lives include the contractual term of any agreement related to the asset, the historical performance of the asset, our long-term strategy for using the asset, any laws or other local regulations that could impact the useful life of the asset, and other economic factors, including competition and specific market conditions. As of June 30, 2016 and December 31, 2015, the Company expended $30,400 and $10,400 in costs for submitting the application for patent rights and trademark which includes patent rights assigned by our Officer to the Company. New Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The following summary of significant accounting policies of the Company is presented to assist in the understanding of the Company’s financial statements. The financial statements and notes are the representation of the Company’s management who is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America ("GAAP") in all material respects, and have been consistently applied in preparing the accompanying financial statements. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates of valuation of equity instruments. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and on deposit at banking institutions. The Company did not have cash equivalents as of December 31, 2015 and 2014, respectively. Concentration of R isk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high quality banking institutions. The Company did not have cash balances in excess of the Federal Deposit Insurance Corporation limit as of December 31, 2015. Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “ Income Taxes” The Company follows the provisions of ASC 740-10, “ Accounting for Uncertain Income Tax Positions Earnings (Loss) Per Common Share The Company computes net earnings (loss) per share in accordance with ASC 260, “ Earnings per Share” Fair value of Financial Instruments and Fair Value Measurements ASC 820, “ Fair Value Measurements and Disclosures”, Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments consist principally of cash, accounts payable, payable to a related party and short term advance. Pursuant to ASC 820 and ASC 825, “ Financial Instruments” Patents and Trademarks Patents and trademarks which are stated at cost, relate to the cost of applications submitted for obtaining patent and trademark of our Dynamic Repair Device, a non-invasive treatment device. Cost is based on third party expenditures for patent applications. We will begin amortizing our patents and trademarks over their estimated remaining useful life when we begin revenue-producing activities. We will determine the useful lives of patents and trademarks after considering the specific facts and circumstances related to each such asset. Factors we consider when determining useful lives include the contractual term of any agreement related to the asset, the historical performance of the asset, our long-term strategy for using the asset, any laws or other local regulations that could impact the useful life of the asset, and other economic factors, including competition and specific market conditions. As of December 31, 2015, the Company expended $10,400 in costs for submitting the application for patents and trademarks. New Accounting Pronouncements In May 2014, and later amended in August 2015, the Financial Accounting Standards Board (“FASB”) issued new Accounting Standards Update (“ASU”) regarding revenue recognition under GAAP. This new guidance will supersede nearly all existing revenue recognition guidance and, and is effective for public entities for annual and interim periods beginning after December 31, 2017. Early adoption is permitted for reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact of this new guidance on the Company’s financial statements. In August 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-15, “Presentation of Financial Statements Going Concern”, which requires management to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and interim periods thereafter. The guidance is not expected to have a material impact on the Company’s financial statements. In April 2015, FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs, which changes the presentation of debt issuance costs in financial statements. ASU 2015-03 requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of debt issuance costs will continue to be reported as interest expense. ASU 2015-03 is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The guidance is not expected to have a material impact on the Company’s financial statements. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. The amendments in this update simplify the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. These amendments may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. The amendments are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. The guidance is not expected to have a material impact on the Company’s financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 840), to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The amendments in this standard are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, for a public entity. Early adoption of the amendments in this standard is permitted for all entities and the Company must recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently in the process of evaluating the effect this guidance will have on its financial statements and related disclosures. The Financial Accounting Standards Board issues Accounting Standard Updates to amend the authoritative literature in ASC. There have been a number of ASUs to date that amend the original text of ASC. The Company believes those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company. The Company has implemented all new accounting pronouncements that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Note 3 - Related Party Transact

Note 3 - Related Party Transactions	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 4 – RELATED PARTY TRANSACTIONS On September 16, 2015, Everrich Global Investments Limited (“Everrich”), an entity owned and controlled by Wisdom Qiao, the Chief Executive Officer of the Company (the “Officer”), entered into an agreement with Tiber Creek Corporation (“Tiber Creek”), an entity controlled by the founders of the Company, to exercise a change in control of the Company. Upon the change in control of the Company, the existing shareholders of Tiber Creek retained 500,000 common shares of the Company and the remaining outstanding shares were returned to the Company. In full satisfaction of the services of Tiber Creek, Everrich agreed to pay a non-refundable consideration of $85,000 in legal and professional fees to Tiber Creek. The Officer has paid, on behalf of the Company, $80,000 of the consideration to Tiber Creek and the remaining $5,000 is recorded as accounts payable as of June 30, 2016. On January 26, 2016, the Company’s Board of Directors approved and ratified the assignment (the “Assignment”) by the Officer of her entire right, title and ownership interest in a patent application entitled “DYNAMIC RECOVERY AND THERAPY SYSTEM” (the “Invention”) in exchange for 200,000,000 shares of the Company’s common stock. Pursuant to the Assignment, on January 26, 2016, the Company issued 200,000,000 shares of its common stock to its Officer and valued them at $20,000. The transfer of nonmonetary asset by its Officer in exchange of common stock is recorded at the Officer’s historical cost basis determined under USGAAP. Since the common stock of the Company is closely held and not traded, estimating the fair value of the common stock issued is not appropriate. Therefore, upon the assignment of entire right, title and ownership interest in patent application by the Officer to the Company in exchange for 200,000,000 shares of the Company’s common stock, the Company valued the patent rights, title and ownership at its historical cost which approximated $20,000 (Note 7). The Officer has occasionally provided short term advances to the Company for opening its bank accounts and payments to vendors for performing services to the Company. The short term advances are non-interest bearing, unsecured and due on demand. For the six months ended June 30, 2016, the Company received $2,500 from the Officer to settle Amchi’s obligation to a consultant, and paid to the Officer $92,313 towards the advances provided for its working capital needs. The Company is indebted to the Officer $12,359 and $102,172 due and payable as of June 30, 2016 and December 31, 2015, respectively. In addition, the Company is indebted to the Officer $30,000 and $30,000 for compensation for the three months and six months ended June 30, 2016. No compensation was earned or paid to the Officer in the comparable periods of 2015	NOTE 3 – RELATED PARTY TRANSACTIONS On September 16, 2016, Everrich Global Investments Limited (“Everrich”), an entity controlled by the Chief Executive Officer of the Company (the “Officer”), entered into an agreement with Tiber Creek Corporation (“Tiber Creek”), an entity controlled by the founders of the Company, to combine Everrich with a United States reporting company (the “Company”). Upon the change in control of the Company, the existing shareholders of Tiber Creek will retain 500,000 common shares of the Company for continuing as consultant compensation and the remaining outstanding shares will be returned to the Company (Note 6). In full satisfaction of the services of Tiber Creek, Everrich will pay a non-refundable consideration of $85,000 in legal and professional fees to Tiber Creek. The Company has recorded the legal fees expense of $85,000 as of December 31, 2015. The Officer has paid on behalf of the Company $70,000 of the consideration to Tiber Creek during 2015 and the remaining $15,000 is recorded as accounts payable as of December 31, 2015. The Officer has occasionally provided short term advances to the Company for opening its bank accounts and payments to vendors for performing services to the Company. The short term advances are non-interest bearing, unsecured and due on demand. The Company is indebted to the Officer $102,172 and $0 due and payable as of December 31, 2015 and 2014, respectively.

Note 4 - Deposits

Note 4 - Deposits	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Deposits for Purchase of Common Shares [Text Block]	NOTE 5 – DEPOSITS The Company received cash deposits of $0 and $60,445 as of June 30, 2016 and December 31, 2015, respectively, from two investors for purchase of common shares pursuant to a prospective private placement for sale of its common stock in January 2016. The deposits received from two investors were converted into equity by issuance of 218,000 shares of common stock pursuant to the private placement (Note 7).	NOTE 4 – DEPOSITS As of December 31, 2015, the Company had received cash deposits of $60,445 for purchase of common shares pursuant to a prospective private placement. The private placement for sale of common shares took place in January 2016, and such deposits received were converted into equity by issuance of 218,000 shares of common shares to two investors (Note 8) as of the date of this report.

Note 5 - Commitments and Contin

Note 5 - Commitments and Contingencies	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 6 – COMMITMENTS AND CONTINGENCIES Legal Costs and Contingencies In the normal course of business, the Company incurs costs to hire and retain external legal counsel to advise it on regulatory, litigation and other matters. The Company expenses these costs as the related services are received. On February 11, 2016, the Company entered into a Product Design Service Agreement (“Design Agreement”) with Focus Product Design, a California corporation, to design product requirements, systems architecture, proof of concept ME and EE, part sourcing, product architecture, etc. for a fixed fee of $635,100. The Company had paid to Focus Product Design $7,400 towards the product design cost which was recorded as a prepaid expense as of December 31, 2015. The cost of product design has been expensed during the period ended June 30, 2016. On July 24, 2016, the parties mutually agreed to terminate Design Agreement and no additional costs are due to Focus Product Design as of the date of termination. If a loss is considered probable and the amount can be reasonable estimated, the Company recognizes an expense for the estimated loss. If the Company has the potential to recover a portion of the estimated loss from a third party, the Company makes a separate assessment of recoverability and reduces the estimated loss if recovery is also deemed probable.	NOTE 5 – COMMITMENTS AND CONTINGENCIES Legal Costs and Contingencies In the normal course of business, the Company incurs costs to hire and retain external legal counsel to advise it on regulatory, litigation and other matters. The Company expenses these costs as the related services are received. If a loss is considered probable and the amount can be reasonable estimated, the Company recognizes an expense for the estimated loss. If the Company has the potential to recover a portion of the estimated loss from a third party, the Company makes a separate assessment of recoverability and reduces the estimated loss if recovery is also deemed probable.

Note 6 - Stockholders' Equity

Note 6 - Stockholders' Equity	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 7 – STOCKHOLDERS’ EQUITY The Company’s capitalization at June 30, 2016 was 500,000,000 authorized common shares with a par value of $0.0001 per share, and 20,000,000 authorized preferred shares with a par value of $0.0001 per share. Common stock On January 15, 2016, the Company completed a private placement of 26,707,994 shares of its common stock to 37 investors (the “Investors”) for a total purchase price of $647,655. All of the sales were made in China and all of the Investors were residents of China. The Company has issued the share certificates to all 37 investors as of June 30, 2016. All of the stock certificates issued to the Investors have been affixed with an appropriate legend restricting sales and transfers. Therefore, based on the foregoing, the Company has issued the shares in reliance upon the exemptions from registration provided by Section 4a (2) of the Securities Act of 1933 and/or Regulation S. On January 26, 2016, the Company’s Board of Directors approved and ratified the assignment (the “Assignment”) by Wisdom Qiao, the CEO, director and principal shareholder of the Company (“Officer”), of her entire right, title and interest in a patent application entitled “DYNAMIC RECOVERY AND THERAPY SYSTEM” (the “Invention”) in exchange for 200,000,000 shares of the Company’s common stock. Pursuant to the Assignment, on January 26, 2016, the Company issued to its Officer 200,000,000 shares of its common stock valued at $20,000 (Note 4). The shares are restricted and the certificates have been affixed with the appropriate legend restricting sales and transfers. As a result of all common stock issuances, the total outstanding shares of common stock at June 30, 2016 were 247,207,994. Preferred stock At June 30, 2016, the Company had no shares of preferred stock issued or outstanding.	NOTE 6 – STOCKHOLDERS’ EQUITY The Company’s capitalization at December 31, 2015 was 500,000,000 authorized common shares with a par value of $0.0001 per share, and 20,000,000 authorized preferred shares with a par value of $0.0001 per share. Common stock On May 20, 2014 the Company issued 20,000,000 shares of common stock at par value of $0.0001 per share to two directors and officers at a discount of $2,000. On October 14, 2015 the Company effected a change in control and redeemed 19,500,000 shares of its then outstanding 20,000,000 shares of common stock upon the resignation of two directors (Note 3). On October 15, 2015, the Company issued 20,000,000 shares of its common stock at par value, at a discount of $2,000, pursuant to Section 4(2) of the Securities Act of 1933 to Wisdom Qiao, Chief Executive Officer, the sole officer and director of the Company. On October 20, 2015, the Company filed with the State of Delaware a certificate of amendment to its Certificate of Incorporation increasing its authorized shares of $.0001 par value common stock from 100,000,000 to 500,000,000 and authorizing 20,000,000 shares of preferred stock, $.0001 par value. As a result of all common stock issuances, the total outstanding shares of common stock at December 31, 2015 were 20,500,000. Preferred stock At December 31, 2015, the Company had no shares of preferred stock issued or outstanding.

Note 7 - Income Tax

Note 7 - Income Tax	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 7 - INCOME TAX The following is a reconciliation of the provision for income taxes at the U.S. federal income tax rate of 34% and 8.7% state income tax rate for Delaware for the years ended December 31, 2015 and 2014, respectively, to the income taxes reflected in the Statements of Operations: For the year ended December 31, 201 5 201 4 Tax expense at statutory rate - federal (34.00)% (34.00)% State tax expense, net of federal benefit (5.74)% (5.74) Valuation allowance 39.74% 39.74% Tax expense at actual rate - - The tax effects of temporary differences that gave rise to significant portions of deferred tax assets and liabilities at December 31, 2015 and 2014 are as follows: For the year ended December 31, 201 5 201 4 Deferred tax assets and liabilities: Net operating loss carry forward $ 40,430 $ 281 Valuation allowance $ (40,430 ) $ (281 ) Net deferred tax assets - - Deferred income taxes are provided for the tax effects of transactions reported in the financial statements and consist of deferred taxes related primarily to differences between the bases of certain assets and liabilities for financial and tax reporting. The deferred taxes represent the future tax return consequences of those differences, which will either be deductible or taxable when the assets and liabilities are recovered or settled. At December 31, 2015 and 2014, the Company had net operating loss carry-forwards of approximately $101,700 and $700 resulting in deferred tax assets recorded of $40,430 and $281, respectively, which begin to expire in 2034. The Company has recorded a 100% valuation allowance on the deferred tax assets due to the uncertainty of its realization. The net change in the valuation allowance for the years ended December 31, 2015 and 2014 was an increase of $40,149 and $281, respectively. In the normal course of business, the Company’s income tax returns are subject to examination by various taxing authorities. Such examinations may result in future tax and interest assessment by these taxing authorities. Accordingly, the Company believes that it is more likely than not that it will realize the benefits of tax positions it has taken in its tax returns or for the amount of any tax benefit that exceeds the cumulative probability threshold in accordance with FASB ASC 740-10-15. Differences between the estimated and actual amounts determined upon ultimate resolution, individually or in the aggregate, are not expected to have a material adverse effect on the company’s financial position. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for unrecognized tax benefits. As of December 31, 2015, tax year 2014 remains open for IRS audit. The Company has received no notice of audit from the Internal Revenue Service for any of the open tax years.

Note 8 - Subsequent Events

Note 8 - Subsequent Events	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 7 – SUBSEQUENT EVENTS The Company has evaluated subsequent events and transactions that occurred through the date and time our financial statements were issued for potential recognition or disclosure in the accompanying financial statements.	NOTE 8 – SUBSEQUENT EVENTS The Company has evaluated subsequent events and transactions that occurred through the date and time our financial statements were issued for potential recognition or disclosure in the accompanying financial statements. On January 15, 2016 the Company completed a private placement of 26,707,994 shares of its common stock to 37 investors (the “Investors”) for a total purchase price of $647,610. All of the sales were made in China and all of the Investors were residents of China. The Company has issued the share certificates to all 37 investors as of the date of this report. No commissions were paid. The Investors have acquired their shares for investment and not with a view toward distribution. All of the stock certificates issued to the Investors have been affixed with an appropriate legend restricting sales and transfers. Therefore, based on the foregoing, the Company has issued the shares in reliance upon the exemptions from registration provided by Section 4a (2) of the Securities Act of 1933 and/or Regulation S. On January 26, 2016, the Company’s Board of Directors approved and ratified the assignment (the “Assignment”) by Wisdom Qiao, the CEO, director and principal shareholder of the Company, of her entire right, title and interest in a patent application entitled “DYNAMIC RECOVERY AND THERAPY SYSTEM” (the “Invention”) in exchange for 200,000,000 shares of the Company’s common stock. Pursuant to the Assignment, the Company has issued 200,000,000 shares of its common stock to Wisdom Qiao, the Company’s CEO, director and principal shareholder as of the date of this report. The shares are restricted and the certificates have been affixed with the appropriate legend restricting sales and transfers. The application was filed with the United States Patent Office on September 22, 2015. The Invention is a massage device with predetermined patterns, pressures and methods, designed to provide health benefits to improve physical fitness, reduce blood pressure, reduce glucose levels, enhance sleep and potentially reduce or eliminate tumor growth. On February 11, 2016, the Company entered into a Product Design Service Agreement with Focus Product Design, a California corporation, to design product requirements, systems architecture, proof of concept ME and EE, part sourcing, product architecture, etc. for a fixed fee of $635,100. The agreement will continue to be effective until performed by Focus. The Company has paid to Focus Product Design $7,400 and recorded the expense as a prepaid expense in the accompanying financial statements as of December 31, 2015.

Note 1 - Nature of Operations19

Note 1 - Nature of Operations and Going Concern	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 1 – NATURE OF OPERATIONS AND GOING CONCERN As used herein and except as otherwise noted, the term “Company”, “it(s)”, “our”, “us”, “we” and “Amchi” shall mean Amchi Gendynamy Science Corporation, a Delaware corporation. Amchi Gendynamy Science Corporation, formerly known as Pretty Valley Acquisition Corporation, was incorporated on May 20, 2014 under the laws of the state of Delaware. On June 18, 2014, Pretty Valley Acquisition Corporation filed a registration statement with the Securities and Exchange Commission on Form 10 by which it became a public reporting company. In September, 2015, the Company implemented a change of control by redeeming shares of existing shareholders, issuing shares to new shareholders, electing new officers and directors and accepting the resignations of its then existing officers and directors. In connection with the change of control, the shareholders of the Company and its board of directors unanimously approved the change of the Company’s name from Pretty Valley Acquisition Corporation to Amchi Gendynamy Science Corporation. The Company has been formed to provide a method for a foreign or domestic private company to become a reporting company with a class of securities registered under the Securities Exchange Act of 1934. The Company is an early-stage development company using a special designed message machine along with acoustic wave to replace medicine and insulin to help diabetes patients to recovery from high blood sugar and medicine side effects. In China, Amchi is one of a few companies in the field of developing a physical method to treat Diabetes, utilizing electrical frequencies and special acoustic waves, which the founder of the Company has devoted many years in researching this Chinese traditional sound wave treatment. The Company has been working to determine what is the right multiple frequency, and how this frequency works on Diabetes to lower blood sugar. The Company’s research is in its early stages and there is no assurance that its therapy protocol or its energy devices will ever be able to be proved and accepted by the scientific and medical communities. Going Concern The Company’s financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet generated any revenue and has sustained operating losses since inception to date and allow it to continue as a going concern. The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, the ability of the Company to obtain necessary financing to continue operations, and the attainment of profitable operations. The Company incurred a net loss of $116,830 for the six months ended June 30, 2016, used net cash in operating activities of $232,848, has a working capital surplus of $420,445, and has an accumulated deficit of $218,561as of June 30, 2016. These factors, among others raise a substantial doubt regarding the Company’s ability to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations. The accompanying financial statements do not include any adjustments to reflect the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.	NOTE 1 – NATURE OF OPERATIONS AND GOING CONCERN As used herein and except as otherwise noted, the term “Company”, “it(s)”, “our”, “us”, “we” and “Amchi” shall mean Amchi Gendynamy Science Corporation, a Delaware corporation. Amchi Gendynamy Science Corporation (formerly Pretty Valley Acquisition Corporation ("Amchi Gendynamy" or the "Company") was incorporated on May 20, 2014 under the laws of the state of Delaware to engage research and develop Dynamic recovery and therapy system, we will concentrated on develop the theory and application of Dynamic recovery and therapy Device, will continue to commercialize such Device around the world. We own the technology of Dynamic recovery and therapy technology, not bought for the others. Going Concern The Company’s financial statements are prepared using generally accepted accounting principles in the United States of America applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not yet generated any revenue and has sustained operating losses since inception to date and allow it to continue as a going concern. The continuation of the Company as a going concern is dependent upon the continued financial support from its shareholders, the ability of the Company to obtain necessary financing to continue operations, and the attainment of profitable operations. The Company incurred a net loss of $101,024 for the year ended December 31, 2015, provided net cash in operating activities of $9,792, had a working capital deficit of $110,380, and has an accumulated deficit of $101,731 as of December 31, 2015. These factors, among others raise a substantial doubt regarding the Company’s ability to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations. The accompanying financial statements do not include any adjustments to reflect the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 2 - Summary of Significa20

Note 2 - Summary of Significant Accounting Policies	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The following summary of significant accounting policies of the Company is presented to assist in the understanding of the Company’s financial statements. The financial statements and notes are the representation of the Company’s management who is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America ("GAAP") in all material respects, and have been consistently applied in preparing the accompanying financial statements. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates of valuation of equity instruments. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and on deposit at the banking institutions. The Company did not have cash equivalents as of June 30, 2016 and December 31, 2015, respectively. Concentration of Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and other current asset. The Company places its cash with high quality banking institutions. The Company has the cash balances in excess of the Federal Deposit Insurance Corporation limit as of June 30, 2016 and not as of December 31, 2015. Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “ Income Taxes” The Company follows the provisions of ASC 740-10, “ Accounting for Uncertain Income Tax Positions Earnings (Loss) Per Common Share The Company computes net earnings (loss) per share in accordance with ASC 260, “ Earnings per Share” Fair value of Financial Instruments and Fair Value Measurements ASC 820, “ Fair Value Measurements and Disclosures”, Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments consist principally of cash, other current asset, accounts payable, payable to a related party and short term deposits. Pursuant to ASC 820 and ASC 825, “ Financial Instruments” Patent Rights and Trademark Patent rights and trademarks which are stated at cost, relate to the cost of applications submitted for obtaining patent and trademark of our Genome Repair Device, a non-invasive treatment device. Cost is based on third party expenditures for patent applications. We will begin amortizing our patent rights and trademark over their estimated remaining useful life when we begin revenue-producing activities. We will determine the useful lives of patent rights and trademark after considering the specific facts and circumstances related to each such asset. Factors we consider when determining useful lives include the contractual term of any agreement related to the asset, the historical performance of the asset, our long-term strategy for using the asset, any laws or other local regulations that could impact the useful life of the asset, and other economic factors, including competition and specific market conditions. As of June 30, 2016 and December 31, 2015, the Company expended $30,400 and $10,400 in costs for submitting the application for patent rights and trademark which includes patent rights assigned by our Officer to the Company. New Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The following summary of significant accounting policies of the Company is presented to assist in the understanding of the Company’s financial statements. The financial statements and notes are the representation of the Company’s management who is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America ("GAAP") in all material respects, and have been consistently applied in preparing the accompanying financial statements. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates of valuation of equity instruments. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and on deposit at banking institutions. The Company did not have cash equivalents as of December 31, 2015 and 2014, respectively. Concentration of R isk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high quality banking institutions. The Company did not have cash balances in excess of the Federal Deposit Insurance Corporation limit as of December 31, 2015. Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “ Income Taxes” The Company follows the provisions of ASC 740-10, “ Accounting for Uncertain Income Tax Positions Earnings (Loss) Per Common Share The Company computes net earnings (loss) per share in accordance with ASC 260, “ Earnings per Share” Fair value of Financial Instruments and Fair Value Measurements ASC 820, “ Fair Value Measurements and Disclosures”, Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments consist principally of cash, accounts payable, payable to a related party and short term advance. Pursuant to ASC 820 and ASC 825, “ Financial Instruments” Patents and Trademarks Patents and trademarks which are stated at cost, relate to the cost of applications submitted for obtaining patent and trademark of our Dynamic Repair Device, a non-invasive treatment device. Cost is based on third party expenditures for patent applications. We will begin amortizing our patents and trademarks over their estimated remaining useful life when we begin revenue-producing activities. We will determine the useful lives of patents and trademarks after considering the specific facts and circumstances related to each such asset. Factors we consider when determining useful lives include the contractual term of any agreement related to the asset, the historical performance of the asset, our long-term strategy for using the asset, any laws or other local regulations that could impact the useful life of the asset, and other economic factors, including competition and specific market conditions. As of December 31, 2015, the Company expended $10,400 in costs for submitting the application for patents and trademarks. New Accounting Pronouncements In May 2014, and later amended in August 2015, the Financial Accounting Standards Board (“FASB”) issued new Accounting Standards Update (“ASU”) regarding revenue recognition under GAAP. This new guidance will supersede nearly all existing revenue recognition guidance and, and is effective for public entities for annual and interim periods beginning after December 31, 2017. Early adoption is permitted for reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact of this new guidance on the Company’s financial statements. In August 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-15, “Presentation of Financial Statements Going Concern”, which requires management to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and interim periods thereafter. The guidance is not expected to have a material impact on the Company’s financial statements. In April 2015, FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs, which changes the presentation of debt issuance costs in financial statements. ASU 2015-03 requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of debt issuance costs will continue to be reported as interest expense. ASU 2015-03 is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The guidance is not expected to have a material impact on the Company’s financial statements. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. The amendments in this update simplify the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. These amendments may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. The amendments are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. The guidance is not expected to have a material impact on the Company’s financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 840), to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The amendments in this standard are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, for a public entity. Early adoption of the amendments in this standard is permitted for all entities and the Company must recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently in the process of evaluating the effect this guidance will have on its financial statements and related disclosures. The Financial Accounting Standards Board issues Accounting Standard Updates to amend the authoritative literature in ASC. There have been a number of ASUs to date that amend the original text of ASC. The Company believes those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company. The Company has implemented all new accounting pronouncements that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Note 3 - Other Current Asset

Note 3 - Other Current Asset	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Other Current Assets [Text Block]	NOTE 3 – OTHER CURRENT ASSET In April 2016, the Company received a notice from the State of Delaware that Amchi is delinquent in filing its Annual Franchise Tax Report for the tax year 2015. The Company was required to pay a franchise tax of $144,070 and interest and penalty of $4,501 for a total consideration of $148,571. The Company made the payment of $148,571 on April 27, 2016. Upon further review, the Company followed up with the Delaware Franchise Tax department and was informed that Amchi had previously paid the required annual franchise tax for 2015, and there was a computer error in sending out the delinquent tax notice. The Company is currently completing the formalities to receive the refund from the State of Delaware Franchise Tax and expect to receive $148,571 refund in full.

Note 4 - Related Party Transact

Note 4 - Related Party Transactions	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 4 – RELATED PARTY TRANSACTIONS On September 16, 2015, Everrich Global Investments Limited (“Everrich”), an entity owned and controlled by Wisdom Qiao, the Chief Executive Officer of the Company (the “Officer”), entered into an agreement with Tiber Creek Corporation (“Tiber Creek”), an entity controlled by the founders of the Company, to exercise a change in control of the Company. Upon the change in control of the Company, the existing shareholders of Tiber Creek retained 500,000 common shares of the Company and the remaining outstanding shares were returned to the Company. In full satisfaction of the services of Tiber Creek, Everrich agreed to pay a non-refundable consideration of $85,000 in legal and professional fees to Tiber Creek. The Officer has paid, on behalf of the Company, $80,000 of the consideration to Tiber Creek and the remaining $5,000 is recorded as accounts payable as of June 30, 2016. On January 26, 2016, the Company’s Board of Directors approved and ratified the assignment (the “Assignment”) by the Officer of her entire right, title and ownership interest in a patent application entitled “DYNAMIC RECOVERY AND THERAPY SYSTEM” (the “Invention”) in exchange for 200,000,000 shares of the Company’s common stock. Pursuant to the Assignment, on January 26, 2016, the Company issued 200,000,000 shares of its common stock to its Officer and valued them at $20,000. The transfer of nonmonetary asset by its Officer in exchange of common stock is recorded at the Officer’s historical cost basis determined under USGAAP. Since the common stock of the Company is closely held and not traded, estimating the fair value of the common stock issued is not appropriate. Therefore, upon the assignment of entire right, title and ownership interest in patent application by the Officer to the Company in exchange for 200,000,000 shares of the Company’s common stock, the Company valued the patent rights, title and ownership at its historical cost which approximated $20,000 (Note 7). The Officer has occasionally provided short term advances to the Company for opening its bank accounts and payments to vendors for performing services to the Company. The short term advances are non-interest bearing, unsecured and due on demand. For the six months ended June 30, 2016, the Company received $2,500 from the Officer to settle Amchi’s obligation to a consultant, and paid to the Officer $92,313 towards the advances provided for its working capital needs. The Company is indebted to the Officer $12,359 and $102,172 due and payable as of June 30, 2016 and December 31, 2015, respectively. In addition, the Company is indebted to the Officer $30,000 and $30,000 for compensation for the three months and six months ended June 30, 2016. No compensation was earned or paid to the Officer in the comparable periods of 2015	NOTE 3 – RELATED PARTY TRANSACTIONS On September 16, 2016, Everrich Global Investments Limited (“Everrich”), an entity controlled by the Chief Executive Officer of the Company (the “Officer”), entered into an agreement with Tiber Creek Corporation (“Tiber Creek”), an entity controlled by the founders of the Company, to combine Everrich with a United States reporting company (the “Company”). Upon the change in control of the Company, the existing shareholders of Tiber Creek will retain 500,000 common shares of the Company for continuing as consultant compensation and the remaining outstanding shares will be returned to the Company (Note 6). In full satisfaction of the services of Tiber Creek, Everrich will pay a non-refundable consideration of $85,000 in legal and professional fees to Tiber Creek. The Company has recorded the legal fees expense of $85,000 as of December 31, 2015. The Officer has paid on behalf of the Company $70,000 of the consideration to Tiber Creek during 2015 and the remaining $15,000 is recorded as accounts payable as of December 31, 2015. The Officer has occasionally provided short term advances to the Company for opening its bank accounts and payments to vendors for performing services to the Company. The short term advances are non-interest bearing, unsecured and due on demand. The Company is indebted to the Officer $102,172 and $0 due and payable as of December 31, 2015 and 2014, respectively.

Note 5 - Deposits

Note 5 - Deposits	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Deposits for Purchase of Common Shares [Text Block]	NOTE 5 – DEPOSITS The Company received cash deposits of $0 and $60,445 as of June 30, 2016 and December 31, 2015, respectively, from two investors for purchase of common shares pursuant to a prospective private placement for sale of its common stock in January 2016. The deposits received from two investors were converted into equity by issuance of 218,000 shares of common stock pursuant to the private placement (Note 7).	NOTE 4 – DEPOSITS As of December 31, 2015, the Company had received cash deposits of $60,445 for purchase of common shares pursuant to a prospective private placement. The private placement for sale of common shares took place in January 2016, and such deposits received were converted into equity by issuance of 218,000 shares of common shares to two investors (Note 8) as of the date of this report.

Note 6 - Commitments and Contin

Note 6 - Commitments and Contingencies	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 6 – COMMITMENTS AND CONTINGENCIES Legal Costs and Contingencies In the normal course of business, the Company incurs costs to hire and retain external legal counsel to advise it on regulatory, litigation and other matters. The Company expenses these costs as the related services are received. On February 11, 2016, the Company entered into a Product Design Service Agreement (“Design Agreement”) with Focus Product Design, a California corporation, to design product requirements, systems architecture, proof of concept ME and EE, part sourcing, product architecture, etc. for a fixed fee of $635,100. The Company had paid to Focus Product Design $7,400 towards the product design cost which was recorded as a prepaid expense as of December 31, 2015. The cost of product design has been expensed during the period ended June 30, 2016. On July 24, 2016, the parties mutually agreed to terminate Design Agreement and no additional costs are due to Focus Product Design as of the date of termination. If a loss is considered probable and the amount can be reasonable estimated, the Company recognizes an expense for the estimated loss. If the Company has the potential to recover a portion of the estimated loss from a third party, the Company makes a separate assessment of recoverability and reduces the estimated loss if recovery is also deemed probable.	NOTE 5 – COMMITMENTS AND CONTINGENCIES Legal Costs and Contingencies In the normal course of business, the Company incurs costs to hire and retain external legal counsel to advise it on regulatory, litigation and other matters. The Company expenses these costs as the related services are received. If a loss is considered probable and the amount can be reasonable estimated, the Company recognizes an expense for the estimated loss. If the Company has the potential to recover a portion of the estimated loss from a third party, the Company makes a separate assessment of recoverability and reduces the estimated loss if recovery is also deemed probable.

Note 7 - Stockholders' Equity

Note 7 - Stockholders' Equity	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 7 – STOCKHOLDERS’ EQUITY The Company’s capitalization at June 30, 2016 was 500,000,000 authorized common shares with a par value of $0.0001 per share, and 20,000,000 authorized preferred shares with a par value of $0.0001 per share. Common stock On January 15, 2016, the Company completed a private placement of 26,707,994 shares of its common stock to 37 investors (the “Investors”) for a total purchase price of $647,655. All of the sales were made in China and all of the Investors were residents of China. The Company has issued the share certificates to all 37 investors as of June 30, 2016. All of the stock certificates issued to the Investors have been affixed with an appropriate legend restricting sales and transfers. Therefore, based on the foregoing, the Company has issued the shares in reliance upon the exemptions from registration provided by Section 4a (2) of the Securities Act of 1933 and/or Regulation S. On January 26, 2016, the Company’s Board of Directors approved and ratified the assignment (the “Assignment”) by Wisdom Qiao, the CEO, director and principal shareholder of the Company (“Officer”), of her entire right, title and interest in a patent application entitled “DYNAMIC RECOVERY AND THERAPY SYSTEM” (the “Invention”) in exchange for 200,000,000 shares of the Company’s common stock. Pursuant to the Assignment, on January 26, 2016, the Company issued to its Officer 200,000,000 shares of its common stock valued at $20,000 (Note 4). The shares are restricted and the certificates have been affixed with the appropriate legend restricting sales and transfers. As a result of all common stock issuances, the total outstanding shares of common stock at June 30, 2016 were 247,207,994. Preferred stock At June 30, 2016, the Company had no shares of preferred stock issued or outstanding.	NOTE 6 – STOCKHOLDERS’ EQUITY The Company’s capitalization at December 31, 2015 was 500,000,000 authorized common shares with a par value of $0.0001 per share, and 20,000,000 authorized preferred shares with a par value of $0.0001 per share. Common stock On May 20, 2014 the Company issued 20,000,000 shares of common stock at par value of $0.0001 per share to two directors and officers at a discount of $2,000. On October 14, 2015 the Company effected a change in control and redeemed 19,500,000 shares of its then outstanding 20,000,000 shares of common stock upon the resignation of two directors (Note 3). On October 15, 2015, the Company issued 20,000,000 shares of its common stock at par value, at a discount of $2,000, pursuant to Section 4(2) of the Securities Act of 1933 to Wisdom Qiao, Chief Executive Officer, the sole officer and director of the Company. On October 20, 2015, the Company filed with the State of Delaware a certificate of amendment to its Certificate of Incorporation increasing its authorized shares of $.0001 par value common stock from 100,000,000 to 500,000,000 and authorizing 20,000,000 shares of preferred stock, $.0001 par value. As a result of all common stock issuances, the total outstanding shares of common stock at December 31, 2015 were 20,500,000. Preferred stock At December 31, 2015, the Company had no shares of preferred stock issued or outstanding.

Note 8 - Subsequent Events26

Note 8 - Subsequent Events	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 7 – SUBSEQUENT EVENTS The Company has evaluated subsequent events and transactions that occurred through the date and time our financial statements were issued for potential recognition or disclosure in the accompanying financial statements.	NOTE 8 – SUBSEQUENT EVENTS The Company has evaluated subsequent events and transactions that occurred through the date and time our financial statements were issued for potential recognition or disclosure in the accompanying financial statements. On January 15, 2016 the Company completed a private placement of 26,707,994 shares of its common stock to 37 investors (the “Investors”) for a total purchase price of $647,610. All of the sales were made in China and all of the Investors were residents of China. The Company has issued the share certificates to all 37 investors as of the date of this report. No commissions were paid. The Investors have acquired their shares for investment and not with a view toward distribution. All of the stock certificates issued to the Investors have been affixed with an appropriate legend restricting sales and transfers. Therefore, based on the foregoing, the Company has issued the shares in reliance upon the exemptions from registration provided by Section 4a (2) of the Securities Act of 1933 and/or Regulation S. On January 26, 2016, the Company’s Board of Directors approved and ratified the assignment (the “Assignment”) by Wisdom Qiao, the CEO, director and principal shareholder of the Company, of her entire right, title and interest in a patent application entitled “DYNAMIC RECOVERY AND THERAPY SYSTEM” (the “Invention”) in exchange for 200,000,000 shares of the Company’s common stock. Pursuant to the Assignment, the Company has issued 200,000,000 shares of its common stock to Wisdom Qiao, the Company’s CEO, director and principal shareholder as of the date of this report. The shares are restricted and the certificates have been affixed with the appropriate legend restricting sales and transfers. The application was filed with the United States Patent Office on September 22, 2015. The Invention is a massage device with predetermined patterns, pressures and methods, designed to provide health benefits to improve physical fitness, reduce blood pressure, reduce glucose levels, enhance sleep and potentially reduce or eliminate tumor growth. On February 11, 2016, the Company entered into a Product Design Service Agreement with Focus Product Design, a California corporation, to design product requirements, systems architecture, proof of concept ME and EE, part sourcing, product architecture, etc. for a fixed fee of $635,100. The agreement will continue to be effective until performed by Focus. The Company has paid to Focus Product Design $7,400 and recorded the expense as a prepaid expense in the accompanying financial statements as of December 31, 2015.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates of valuation of equity instruments. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates of valuation of equity instruments. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and on deposit at the banking institutions. The Company did not have cash equivalents as of June 30, 2016 and December 31, 2015, respectively.	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and on deposit at banking institutions. The Company did not have cash equivalents as of December 31, 2015 and 2014, respectively.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and other current asset. The Company places its cash with high quality banking institutions. The Company has the cash balances in excess of the Federal Deposit Insurance Corporation limit as of June 30, 2016 and not as of December 31, 2015.	Concentration of R isk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high quality banking institutions. The Company did not have cash balances in excess of the Federal Deposit Insurance Corporation limit as of December 31, 2015.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “ Income Taxes” The Company follows the provisions of ASC 740-10, “ Accounting for Uncertain Income Tax Positions	Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, “ Income Taxes” The Company follows the provisions of ASC 740-10, “ Accounting for Uncertain Income Tax Positions
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) Per Common Share The Company computes net earnings (loss) per share in accordance with ASC 260, “ Earnings per Share”	Earnings (Loss) Per Common Share The Company computes net earnings (loss) per share in accordance with ASC 260, “ Earnings per Share”
Fair Value Measurement, Policy [Policy Text Block]	Fair value of Financial Instruments and Fair Value Measurements ASC 820, “ Fair Value Measurements and Disclosures”, Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments consist principally of cash, other current asset, accounts payable, payable to a related party and short term deposits. Pursuant to ASC 820 and ASC 825, “ Financial Instruments”	Fair value of Financial Instruments and Fair Value Measurements ASC 820, “ Fair Value Measurements and Disclosures”, Level 1 Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. Level 3 Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments consist principally of cash, accounts payable, payable to a related party and short term advance. Pursuant to ASC 820 and ASC 825, “ Financial Instruments”
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patent Rights and Trademark Patent rights and trademarks which are stated at cost, relate to the cost of applications submitted for obtaining patent and trademark of our Genome Repair Device, a non-invasive treatment device. Cost is based on third party expenditures for patent applications. We will begin amortizing our patent rights and trademark over their estimated remaining useful life when we begin revenue-producing activities. We will determine the useful lives of patent rights and trademark after considering the specific facts and circumstances related to each such asset. Factors we consider when determining useful lives include the contractual term of any agreement related to the asset, the historical performance of the asset, our long-term strategy for using the asset, any laws or other local regulations that could impact the useful life of the asset, and other economic factors, including competition and specific market conditions. As of June 30, 2016 and December 31, 2015, the Company expended $30,400 and $10,400 in costs for submitting the application for patent rights and trademark which includes patent rights assigned by our Officer to the Company.	Patents and Trademarks Patents and trademarks which are stated at cost, relate to the cost of applications submitted for obtaining patent and trademark of our Dynamic Repair Device, a non-invasive treatment device. Cost is based on third party expenditures for patent applications. We will begin amortizing our patents and trademarks over their estimated remaining useful life when we begin revenue-producing activities. We will determine the useful lives of patents and trademarks after considering the specific facts and circumstances related to each such asset. Factors we consider when determining useful lives include the contractual term of any agreement related to the asset, the historical performance of the asset, our long-term strategy for using the asset, any laws or other local regulations that could impact the useful life of the asset, and other economic factors, including competition and specific market conditions. As of December 31, 2015, the Company expended $10,400 in costs for submitting the application for patents and trademarks.
New Accounting Pronouncements, Policy [Policy Text Block]	New Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.	New Accounting Pronouncements In May 2014, and later amended in August 2015, the Financial Accounting Standards Board (“FASB”) issued new Accounting Standards Update (“ASU”) regarding revenue recognition under GAAP. This new guidance will supersede nearly all existing revenue recognition guidance and, and is effective for public entities for annual and interim periods beginning after December 31, 2017. Early adoption is permitted for reporting periods beginning after December 15, 2016. The Company is currently evaluating the impact of this new guidance on the Company’s financial statements. In August 2014, the FASB issued Accounting Standards Update (“ASU”) No. 2014-15, “Presentation of Financial Statements Going Concern”, which requires management to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and interim periods thereafter. The guidance is not expected to have a material impact on the Company’s financial statements. In April 2015, FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs, which changes the presentation of debt issuance costs in financial statements. ASU 2015-03 requires an entity to present such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of debt issuance costs will continue to be reported as interest expense. ASU 2015-03 is effective for annual reporting periods beginning after December 15, 2015. Early adoption is permitted. The guidance is not expected to have a material impact on the Company’s financial statements. In November 2015, the FASB issued ASU 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. The amendments in this update simplify the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. These amendments may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. The amendments are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. The guidance is not expected to have a material impact on the Company’s financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 840), to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The amendments in this standard are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, for a public entity. Early adoption of the amendments in this standard is permitted for all entities and the Company must recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The Company is currently in the process of evaluating the effect this guidance will have on its financial statements and related disclosures. The Financial Accounting Standards Board issues Accounting Standard Updates to amend the authoritative literature in ASC. There have been a number of ASUs to date that amend the original text of ASC. The Company believes those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to the Company, or (iv) are not expected to have a significant impact on the Company. The Company has implemented all new accounting pronouncements that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Note 7 - Income Tax (Tables)

Note 7 - Income Tax (Tables)	12 Months Ended
	Dec. 31, 2015
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	For the year ended December 31, 201 5 201 4 Tax expense at statutory rate - federal (34.00)% (34.00)% State tax expense, net of federal benefit (5.74)% (5.74) Valuation allowance 39.74% 39.74% Tax expense at actual rate - -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	For the year ended December 31, 201 5 201 4 Deferred tax assets and liabilities: Net operating loss carry forward $ 40,430 $ 281 Valuation allowance $ (40,430 ) $ (281 ) Net deferred tax assets - -

Note 1 - Nature of Operations29

Note 1 - Nature of Operations and Going Concern (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		7 Months Ended	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2015
Net Income (Loss) Attributable to Parent	$ (70,639)		$ (116,830)	$ 0	$ (707)	$ (101,024)
Net Cash Provided by (Used in) Operating Activities, Continuing Operations			(232,848)	$ 0	0	9,792
Working Capital Deficit						110,380
Retained Earnings (Accumulated Deficit)	$ (218,561)		$ (218,561)		$ (707)	$ (101,731)

Note 2 - Summary of Significa30

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015	Dec. 31, 2014	Jun. 30, 2015	May 19, 2014
Patents and Trademarks [Member]
Finite-Lived Intangible Assets, Net	$ 30,400	$ 10,400
Cash and Cash Equivalents, at Carrying Value	$ 324,386	$ 59,837	$ 0	$ 0	$ 0
Weighted Average Number Diluted Shares Outstanding Adjustment	0	0	0
Cash, Uninsured Amount		$ 0
Finite-Lived Intangible Assets, Net	$ 30,400	$ 10,400

Note 3 - Related Party Transa31

Note 3 - Related Party Transactions (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		7 Months Ended	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2015	Sep. 16, 2016	Sep. 16, 2015
Tiber Creek [Member] | Legal and Professional Fees, Non-refundable [Member]
Operating Expenses			$ 85,000			$ 85,000
Related Party Transaction, Amounts of Transaction			80,000			70,000
Accounts Payable, Related Parties, Current	$ 5,000		5,000			15,000
Tiber Creek [Member]
Common Stock, Retain, Upon the Change in Control of the Company							$ 500,000	$ 500,000
Officer [Member]
Related Party Transaction, Amounts of Transaction			2,500
Accounts Payable, Related Parties, Current	12,359		12,359		$ 0	102,172
Operating Expenses	70,660		116,876		707	101,024
Accounts Payable, Related Parties, Current	$ 12,359		$ 12,359			$ 102,172

Note 4 - Deposits (Details Text

Note 4 - Deposits (Details Textual)	Jan. 15, 2016shares	Jan. 31, 2016shares	Jun. 30, 2016USD ($)shares	Dec. 31, 2015USD ($)
Private Placement [Member] | Subsequent Event [Member]
Sale of Stock, Number of Shares Issued in Transaction	26,707,994	218,000
Number of Investors	37	2
Private Placement [Member]
Sale of Stock, Number of Shares Issued in Transaction	26,707,994		218,000
Number of Investors	37		2
Deposits, Purchase of Common Shares, Prospective Private Placement | $			$ 0	$ 60,445

Note 6 - Stockholders' Equity (

Note 6 - Stockholders' Equity (Details Textual) - USD ($)	Jan. 26, 2016	Oct. 15, 2015	Oct. 14, 2015	Dec. 31, 2014	Dec. 31, 2015	Jun. 30, 2016	Oct. 20, 2015	Oct. 19, 2015	Oct. 02, 2015
Directors and Officers [Member]
Common Stock, Par or Stated Value Per Share				$ 0.0001
Stock Issued During Period, Shares, New Issues				20,000,000
Common Stock, Discount on Shares, During the Period				$ 2,000
Chief Executive Officer [Member]
Stock Issued During Period, Shares, New Issues	200,000,000	20,000,000
Common Stock, Discount on Shares, During the Period		$ 2,000
Change in Control [Member] | Common Stock [Member]
Stock Redeemed or Called During Period, Shares			19,500,000
Change in Control [Member]
Common Stock, Shares, Outstanding			20,000,000
Common Stock [Member]
Stock Issued During Period, Shares, New Issues				20,000,000	20,000,000
Stock Redeemed or Called During Period, Shares					19,500,000
Preferred Stock, Shares Issued				0	0	0
Preferred Stock, Shares Outstanding				0	0	0
Common Stock, Shares Authorized				500,000,000	500,000,000	500,000,000	500,000,000	100,000,000
Common Stock, Par or Stated Value Per Share				$ 0.0001	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized				20,000,000	20,000,000	20,000,000			20,000,000
Preferred Stock, Par or Stated Value Per Share				$ 0.0001	$ 0.0001	$ 0.0001			$ 0.0001
Common Stock, Discount on Shares, During the Period				$ 0	$ 50
Common Stock, Shares, Outstanding				20,000,000	20,500,000	247,207,994

Note 7 - Income Tax (Details Te

Note 7 - Income Tax (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Delaware Jurisdiction [Member]
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent	(8.70%)	(8.70%)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	(34.00%)	(34.00%)
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent	(5.74%)	(5.74%)
Operating Loss Carryforwards	$ 101,700	$ 700
Deferred Income Tax Assets, Net	$ 40,430	281
Deferred Tax Assets, Valuation Allowance, Percentage	100.00%
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 40,149	$ 281

Note 7 - Reconciliation of the

Note 7 - Reconciliation of the Provision for Income Taxes Rate (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	(34.00%)	(34.00%)
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent	(5.74%)	(5.74%)
Valuation allowance	39.74%	39.74%
Tax expense at actual rate

Note 7 - Deferred Tax Assets an

Note 7 - Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Net operating loss carry forward	$ 40,430	$ 281
Valuation allowance	(40,430)	(281)
Net deferred tax assets

Note 8 - Subsequent Events (Det

Note 8 - Subsequent Events (Details Textual)	Feb. 11, 2016USD ($)	Jan. 26, 2016shares	Jan. 15, 2016USD ($)shares	Oct. 15, 2015shares	Jan. 31, 2016shares	Jun. 30, 2016shares	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Private Placement [Member] | Subsequent Event [Member]
Sale of Stock, Commissions			$ 0
Sale of Stock, Number of Shares Issued in Transaction | shares			26,707,994		218,000
Number of Investors			37		2
Sale of Stock, Consideration Received on Transaction			$ 647,610
Private Placement [Member]
Sale of Stock, Number of Shares Issued in Transaction | shares			26,707,994			218,000
Number of Investors			37			2
Sale of Stock, Consideration Received on Transaction			$ 647,655
Subsequent Event [Member] | Common Stock Exchange for Patent Application [Member] | Chief Executive Officer [Member]
Stock Issued During Period, Shares, New Issues | shares		200,000,000
Subsequent Event [Member] | Focus Product Design [Member]
Product Design Fixed Service Fee	$ 635,100
Common Stock Exchange for Patent Application [Member] | Chief Executive Officer [Member]
Stock Issued During Period, Shares, New Issues | shares		200,000,000
Chief Executive Officer [Member]
Stock Issued During Period, Shares, New Issues | shares		200,000,000		20,000,000
Focus Product Design [Member]
Prepaid Expense, Current							$ 7,400
Product Design Fixed Service Fee	$ 635,100
Prepaid Expense, Current							$ 7,400

Note 1 - Nature of Operations38

Note 1 - Nature of Operations and Going Concern (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		7 Months Ended	12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2015
Net Income (Loss) Attributable to Parent	$ (70,639)		$ (116,830)	$ 0	$ (707)	$ (101,024)
Net Cash Provided by (Used in) Operating Activities, Continuing Operations			(232,848)	$ 0	0	9,792
Working Capital Surplus			420,445
Retained Earnings (Accumulated Deficit)	$ (218,561)		$ (218,561)		$ (707)	$ (101,731)

Note 2 - Summary of Significa39

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Patents and Trademarks [Member]
Finite-Lived Intangible Assets, Net	$ 30,400	$ 10,400
Cash Equivalents, at Carrying Value	$ 0	0
Cash, Uninsured Amount		$ 0
Weighted Average Number Diluted Shares Outstanding Adjustment	0	0	0
Finite-Lived Intangible Assets, Net	$ 30,400	$ 10,400

Note 3 - Other Current Asset (D

Note 3 - Other Current Asset (Details Textual) - Domestic Tax Authority [Member] - Delaware Jurisdiction [Member] - USD ($)	Apr. 27, 2016	Apr. 30, 2016
Franchise Tax		$ 144,070
Interest and Tax Penalty, Costs		$ 4,501
Payments for Other Taxes	$ 148,571

Note 4 - Related Party Transa41

Note 4 - Related Party Transactions (Details Textual) - USD ($)	Jan. 26, 2016	Oct. 15, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2015	Sep. 16, 2016	Sep. 16, 2015
Officer [Member]
Related Party Transaction, Expenses from Transactions with Related Party			$ 30,000	$ 0	$ 30,000	$ 0
Related Party Transaction, Amounts of Transaction					2,500
Accounts Payable, Related Parties, Current			12,359		12,359		$ 0	$ 102,172
Repayments of Related Party Debt					92,313
Chief Executive Officer [Member] | Common Stock Exchange for Patent Application [Member]
Stock Issued During Period, Shares, New Issues	200,000,000
Chief Executive Officer [Member]
Stock Issued During Period, Shares, New Issues	200,000,000	20,000,000
Stock Issued During Period, Value, New Issues	$ 20,000
Tiber Creek [Member] | Legal and Professional Fees, Non-refundable [Member]
Operating Expenses					85,000			85,000
Related Party Transaction, Amounts of Transaction					80,000			70,000
Accounts Payable, Related Parties, Current			5,000		5,000			15,000
Tiber Creek [Member]
Common Stock, Retain, Upon the Change in Control of the Company									$ 500,000	$ 500,000
Operating Expenses			70,660		116,876		707	101,024
Accounts Payable, Related Parties, Current			$ 12,359		$ 12,359			$ 102,172

Note 5 - Deposits (Details Text

Note 5 - Deposits (Details Textual)	Jan. 15, 2016shares	Jun. 30, 2016USD ($)shares	Dec. 31, 2015USD ($)
Private Placement [Member]
Number of Investors	37	2
Sale of Stock, Number of Shares Issued in Transaction | shares	26,707,994	218,000
Deposits, Purchase of Common Shares, Prospective Private Placement | $		$ 0	$ 60,445

Note 6 - Commitments and Cont43

Note 6 - Commitments and Contingencies (Details Textual) - USD ($)	Feb. 11, 2016	Dec. 31, 2015	Dec. 31, 2014
Focus Product Design [Member]
Prepaid Expense, Current		$ 7,400
Product Design Fixed Service Fee	$ 635,100
Prepaid Expense, Current		$ 7,400

Note 7 - Stockholders' Equity (

Note 7 - Stockholders' Equity (Details Textual)	Jan. 26, 2016USD ($)shares	Jan. 15, 2016USD ($)shares	Oct. 15, 2015shares	Jun. 30, 2016$ / sharesshares	Dec. 31, 2015$ / sharesshares	Oct. 20, 2015shares	Oct. 19, 2015shares	Oct. 02, 2015$ / sharesshares	Dec. 31, 2014$ / sharesshares
Private Placement [Member]
Sale of Stock, Number of Shares Issued in Transaction		26,707,994		218,000
Number of Investors		37		2
Sale of Stock, Consideration Received on Transaction | $		$ 647,655
Chief Executive Officer [Member] | Common Stock Exchange for Patent Application [Member]
Stock Issued During Period, Shares, New Issues	200,000,000
Chief Executive Officer [Member]
Stock Issued During Period, Shares, New Issues	200,000,000		20,000,000
Stock Issued During Period, Value, New Issues | $	$ 20,000
Preferred Stock, Shares Issued				0	0				0
Preferred Stock, Shares Outstanding				0	0				0
Common Stock, Shares Authorized				500,000,000	500,000,000	500,000,000	100,000,000		500,000,000
Common Stock, Par or Stated Value Per Share | $ / shares				$ 0.0001	$ 0.0001				$ 0.0001
Preferred Stock, Shares Authorized				20,000,000	20,000,000			20,000,000	20,000,000
Preferred Stock, Par or Stated Value Per Share | $ / shares				$ 0.0001	$ 0.0001			$ 0.0001	$ 0.0001
Common Stock, Shares, Outstanding				247,207,994	20,500,000				20,000,000